This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chintharlapalli, S. Articles by Safe, S. Search for Related Content PubMed PubMed Citation Articles by Chintharlapalli, S. Articles by Safe, S.

Betulinic Acid Inhibits Prostate Cancer Growth through Inhibition of Specificity Protein Transcription Factors

¹ Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas and Departments of ² Veterinary Physiology and Pharmacology and ³ Veterinary Pathobiology, Texas A&M University, College Station, Texas

Requests for reprints: Stephen Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, Veterinary Research Building 410, College Station, TX 77843-4466. Phone: 979-845-5988; Fax: 979-862-4929; E-mail: ssafe{at}cvm.tamu.edu.

Betulinic acid is a pentacyclic triterpene natural product initially identified as a melanoma-specific cytotoxic agent that exhibits low toxicity in animal models. Subsequent studies show that betulinic acid induces apoptosis and antiangiogenic responses in tumors derived from multiple tissues; however, the underlying mechanism of action is unknown. Using LNCaP prostate cancer cells as a model, we now show that betulinic acid decreases expression of vascular endothelial growth (VEGF) and the antiapoptotic protein survivin. The mechanism of these betulinic acid–induced antiangiogenic and proapoptotic responses in both LNCaP cells and in tumors is due to activation of selective proteasome-dependent degradation of the transcription factors specificity protein 1 (Sp1), Sp3, and Sp4, which regulate VEGF and survivin expression. Thus, betulinic acid acts as a novel anticancer agent through targeted degradation of Sp proteins that are highly overexpressed in tumors. [Cancer Res 2007;67(6):2816–23]

This article has been cited by other articles:

				S. Papineni, S. Chintharlapalli, M. Abdelrahim, S.-o. Lee, R. Burghardt, A. Abudayyeh, C. Baker, L. Herrera, and S. Safe Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met Carcinogenesis, July 1, 2009; 30(7): 1193 - 1201. [Abstract] [Full Text] [PDF]

				M. Meissner, G. Reichenbach, M. Stein, I. Hrgovic, R. Kaufmann, and J. Gille Down-regulation of Vascular Endothelial Growth Factor Receptor 2 Is a Major Molecular Determinant of Proteasome Inhibitor-Mediated Antiangiogenic Action in Endothelial Cells Cancer Res., March 1, 2009; 69(5): 1976 - 1984. [Abstract] [Full Text] [PDF]

				S. Konduri, J. Colon, C. H. Baker, S. Safe, J. L. Abbruzzese, A. Abudayyeh, Md. R. Basha, and M. Abdelrahim Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression Mol. Cancer Ther., March 1, 2009; 8(3): 533 - 542. [Abstract] [Full Text] [PDF]

				M. Ganapathy, R. Ghosh, X. Jianping, X. Zhang, R. Bedolla, J. Schoolfield, I-T. Yeh, D. A. Troyer, A. F. Olumi, and A. P. Kumar Involvement of FLIP in 2-Methoxyestradiol-Induced Tumor Regression in Transgenic Adenocarcinoma of Mouse Prostate Model Clin. Cancer Res., March 1, 2009; 15(5): 1601 - 1611. [Abstract] [Full Text] [PDF]

				Y. Song, J. Wu, R. A. Oyesanya, Z. Lee, A. Mukherjee, and X. Fang Sp-1 and c-Myc Mediate Lysophosphatidic Acid-Induced Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cells via a Hypoxia-Inducible Factor-1-Independent Mechanism Clin. Cancer Res., January 15, 2009; 15(2): 492 - 501. [Abstract] [Full Text] [PDF]

				P. Banerjee, M. Sieburg, E. Samuelson, and G. Feuer Human T-Cell Lymphotropic Virus Type 1 Infection of CD34+ Hematopoietic Progenitor Cells Induces Cell Cycle Arrest by Modulation of p21cip1/waf1 and Survivin Stem Cells, December 1, 2008; 26(12): 3047 - 3058. [Abstract] [Full Text] [PDF]

				G. Chadalapaka, I. Jutooru, S. Chintharlapalli, S. Papineni, R. Smith III, X. Li, and S. Safe Curcumin Decreases Specificity Protein Expression in Bladder Cancer Cells Cancer Res., July 1, 2008; 68(13): 5345 - 5354. [Abstract] [Full Text] [PDF]